WallStreetZenWallStreetZen

NASDAQ: CLRB
Cellectar Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their CLRB stock forecasts and price targets.

Forecast return on equity

Is CLRB forecast to generate an efficient return?

Company
-158.32%
Industry
252.48%
Market
228.08%
CLRB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CLRB forecast to generate an efficient return on assets?

Company
-86.56%
Industry
90.65%
CLRB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CLRB earnings per share forecast

What is CLRB's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$12.26
Avg 2 year Forecast
-$7.67
Avg 3 year Forecast
-$4.64

CLRB revenue forecast

What is CLRB's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

CLRB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CLRB$3.62N/AN/A
BCDA$1.45$25.00+1,624.14%Buy
PCSA$0.27$1.00+270.37%Buy
ATHA$3.87N/AN/A
QNRX$10.30N/AN/A
View Top Biotech Stocks

Cellectar Biosciences Stock Forecast FAQ

What is CLRB's earnings growth forecast for 2025-2027?

(NASDAQ: CLRB) Cellectar Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.65%.

Cellectar Biosciences's earnings in 2025 is -$18,851,190.On average, 6 Wall Street analysts forecast CLRB's earnings for 2025 to be -$52,000,155, with the lowest CLRB earnings forecast at -$67,274,814, and the highest CLRB earnings forecast at -$36,463,032. On average, 6 Wall Street analysts forecast CLRB's earnings for 2026 to be -$32,523,524, with the lowest CLRB earnings forecast at -$68,604,520, and the highest CLRB earnings forecast at -$12,287,908.

In 2027, CLRB is forecast to generate -$19,678,462 in earnings, with the lowest earnings forecast at -$28,671,786 and the highest earnings forecast at -$1,068,514.

If you're new to stock investing, here's how to buy Cellectar Biosciences stock.

What is CLRB's revenue growth forecast for 2025-2027?

(NASDAQ: CLRB) Cellectar Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.62%.

Cellectar Biosciences's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast CLRB's revenue for 2025 to be $0, with the lowest CLRB revenue forecast at $0, and the highest CLRB revenue forecast at $0. On average, 5 Wall Street analysts forecast CLRB's revenue for 2026 to be $0, with the lowest CLRB revenue forecast at $0, and the highest CLRB revenue forecast at $0.

In 2027, CLRB is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is CLRB's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CLRB) forecast ROA is -86.56%, which is lower than the forecast US Biotechnology industry average of 90.65%.

What is CLRB's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CLRB) Cellectar Biosciences's current Earnings Per Share (EPS) is -$9.30. On average, analysts forecast that CLRB's EPS will be -$12.26 for 2025, with the lowest EPS forecast at -$15.87, and the highest EPS forecast at -$8.60. On average, analysts forecast that CLRB's EPS will be -$7.67 for 2026, with the lowest EPS forecast at -$16.18, and the highest EPS forecast at -$2.90. In 2027, CLRB's EPS is forecast to hit -$4.64 (min: -$6.76, max: -$0.25).

What is CLRB's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CLRB) forecast ROE is -158.32%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.